Diasorin S.p.a. · MIL:DIA
Diasorin — Investor Day (December 2021)
87 slides from Diasorin's investor day presentation, Dec 17, 2021
Slide 1: Investor Day
INVESTOR DAY ~~ Milan - December 17, 2021 NY
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by DiaSorin S.p.A. ("DiaSorin” or the “Co
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which DiaSorin operates and the beliefs and assumptions of the management of DiaSorin. In addition, the management of DiaS
Slide 4: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Any forward-looking statements contained in this document speak only as of the date of this document and DiaSorin disclaim any obligation to update or revise publicly forward- looking statements. Further information concerning the Group and its business, including factors
Slide 5: Agenda
SEC TIN 1 GROUP OVERVIEW "WE WALK THE TALK" STRATEGIC SETTING SECTION D D IMMUNODIAGNOSTICS MOLECULAR DIAGNOSTICS LICENSED TECHNOLOGIES SECTION 8 1H) FINANCIAL OUTLOOK
Slide 6: Slide 6
Slide 7: Who We Are
WHO WE ARE DIASORIN IS A GROUP COMMITTED TO DEVELOPING PRODUCTS THAT) REQUIRE COMPLEX TECHNOLOGIES AND HIGH-RISK RESEARCH. WITH THE ACQUISITION OF LUMINEX, WE ARE NOW A LEADER IN A WIDER SPECTRUM OF INNOVATIVE TECHNOLOGIES: IN OTHER WORDS, WE NOW ARE SPECIALIST?
Slide 8: The New DiaSorin After Luminex Acquisition
THE NEW DIASORIN AFTER LUMINEX ACQUISITION OUR BUSINESS BY OUR BUSINESS BY GEOGRAPHY TECHNOLOGY* OUR PEOPLE Europe Direct 35% Molecular Diagnostics 36% Row 16% Immunodiagnostics 50% 53% y NORTH AMERICA North America Direct Licensed Technologies _ . SA nore BROADER PRESENCE IN NORTH AMERICA, WITH A S
Slide 9: Main Business Achievements (1/2)
MAIN BUSINESS ACHIEVEMENTS (1/2) TARGETS PRODUCTS LAUNCHED Value Based Care Launch and increase in ) @ QFT LYMEDETECT @ QFTLTB (VBC) the adoption of VBC tests MEMED BV = CALPROTECTIN a a i 30 NEW PRODUCTS New Immunodiagnostic & Strengthen DiaSorin Molecular Diagnostic specialty positioning tests ~ &
Slide 10: Main Business Achievements (2/2)
Decentralization Trend China Manufacturing M&A and Partnerships MAIN BUSINESS ACHIEVEMENTS (2/2) TARGETS PROGRAMS LAUNCHED / UNDER DEVELOPMENT i=) 4 £ LIAJSON'>< ee LAson iQ @ LIAJSON IVES Full-steam launch following Under Development 2 approval of key tests LIAISON® XS + POC PLATFORMS OPENING OF NE
Slide 11: Decentralization vs. Consolidation
DECENTRALIZATION VS. CONSOLIDATION TRENDS: A QUICK REMINDER ( RESHAPING THE LABORATORY CONSOLIDATION SPACE AND THE IVD INDUSTRY DECENTRALIZATION Need for better performance of routine Need for higher efficiency in patient laboratory services Mp management 208 ) ° ° ° ahs dhs } OPPOSITE FORCES ARE (S
Slide 12: The Decentralization Trend Accelerated
THE DECENTRALIZATION TREND ACCELERATED The importance of Healthcare decentralization leads to additional funding for decentralized hospital locations. 2 examples: IO : ae : "RECOVERY AND RESILIENCE FACILITY FOR ITALY” | - Funding proximity healthcare services (Mission 6) Roadblocks to performing dia
Slide 13: What Did the Pandemic Mean for IVD Companies: Key Trends
WHAT DID THE PANDEMIC MEAN FOR IVD COMPANIES: KEY TRENDS INCREASED PUBLIC DECENTRALIZATION AWARENESS OF SPECIALTIES * Central role of diagnostic testing had an impact on * Need for COVID diagnostic tools has brought specialty patients’ and governments’ perceptions testing to smaller-size labs * High
Slide 14: Business Opportunity: Impact of the Pandemic in Our Key Regions
BUSINESS OPPORTUNITY Ey er IMPACT OF THE PANDEMIC IN OUR KEY REGIONS eo Emergency Funding with 2 major goals: 1.to increase testing capacity in order to meet demand 2.to develop new technologies (e.g. RADX® initiative) FDA empowered to bring new assays to the market more efficiently (e.g. MeMed) GRO
Slide 15: Impact on the Healthcare Systems: The Cost of COVID Testing
IMPACT ON THE HEALTHCARE SYSTEMS: THE COST OF COVID TESTING 2021E IVD MARKET 2 MAJOR REVENUE ~100 $/BN CONTRIBUTORS +40% VS. PRE-PANDEMIC COVID ANTIGEN AND RAPID TESTS (POINT-OF-CARE) 40% iY) S> 65% 35% oy (oR) ex-COVID COVID - related G09 ay eres oon COVID MOLECULAR TESTS (PCR) IN THE LAST 12 MONTH
Slide 16: The Cost of COVID-19 Treatment Including Testing
THE COST OF COVID-19 TREATMENT INCLUDING TESTING % of GDP 18.0 13.5 9.0 45 SS Shs sss PS $9 888 88 ESF FESS Eo 388 88 48 3 8 2 OES oe 8 we ceeee: & £% 8s EA AGTESE EEE GPE EF AGT FE? f oe ° “ . é é pe ° § 3 . e ™ 2019 M 2020 WE WALK THE TALK HEALTHCARE EXPENDITURE AS A SHARE OF GDP, 2019 (OR NEAREST
Slide 17: COVID-19 Costs in the U.S. Healthcare System and Impact on Private Hospitals
COVID-19 COSTS IN THE U.S. HEALTHCARE SYSTEM AND IMPACT ON PRIVATE HOSPITALS ESTIMATED IMPACT ON @ ESTIMATED IMPACT ON ii, TW U.S. HEALTHCARE SYSTEM! 2? : U.S. PRIVATE HOSPITALS2 Annual impact from behavioral a . =» A renAnnit 8 . 1 % March 2020 probability of default for U.S. Hospitals +20% / +30%
Slide 18: How Should Diagnostic Companies Address These New Challenges
HOW SHOULD DIAGNOSTIC COMPANIES ADDRESS THESE NEW CHALLENGES DIAGNOSTIC PLAYERS WILL BE REQUIRED TO SHIFT AND ADAPT THEIR APPROACH IN ORDER TO ADDRESS THE CHALLENGES AND CHANGES THAT ARE EMERGING WITHIN THE HEALTHCARE SPACE ofe CONSOLIDATION TREND ROLE OF ARTIFICIAL | ss INTELLIGENCE Platforms with
Slide 19: Slide 19
Slide 20: Key Technologies Overview
KEY TECHNOLOGIES OVERVIEW SPECIALIST? } | A 7 DiaSorin DiaSorin) ZL amninex. Luminex. IMMUNODIAGNOSTICS MOLECULAR DIAGNOSTICS LICENSED TECHNOLOGIES
Slide 21: Immunodiagnostics
IMMUNODIAGNOSTICS
Slide 22: Keep Focusing on Specialties
KEEP FOCUSING ON SPECIALTIES HIGH-ROUTINE TESTS SPECIALTY TESTS 2019 TODAY 42 76 46 85 +4 Respiratory Diseases CLINICAL AREAS Gastro Intestinal Health Inflammation biomarkers - Disease severity Transplant Monitoring Endocrinology Paediatric Infectious Diseases IMMUNODIAGNosTICS MOLECULAR DIAGNOSTICS
Slide 23: LIAISON MeMed BV
LIAISON® MeMed BV MOLECULAR DIAGNosTICS ===————S—SSCLICENSED TECHNOLOGIES
Slide 24: DiaSorin Investor Meeting (Dec 17th 2021)
The Host Response Company DiaSorin Investor Meeting (Dec 17th 2021) Dr Eran Eden, Co-founder & CEO, MeMed
Slide 25: MeMed at a Glance
MeMed at a Glance Headquarters: Landmark FDA clearance Haifa, Israel | Boston, USA Funding & grants >$200M The leader in the emerging field of From leading investors, insurers, Advanced Host-Response Technologies | Confidential US DoD and EU Commission MeMed, Proprietary and Confidential Information
Slide 26: The body's immune system is built to communicate
The body s immune system is built to communicate what s going on. Our mission is to listen. | Confidential MeMed, Proprietary and Confidential Information. This document and its content may not be reproduced, disclosed or passed on to third parties except with the explicit prior consent of MeMed
Slide 27: We started by tackling fever
We started by tackling fever. which leads to some of the biggest healthcare challenges of our time | Confidential MeMed, Proprietary and Confidential Information. This document and its content may not be reproduced, disclosed or passed on to third parties except with the explicit prior consent of Me
Slide 28: Dilemma #1: Bacterial or viral infection?
Dilemma #1: Bacterial or viral infection? 30-50% antibiotic overuse rates1 4 20% antibiotic underuse rates5-7 $1 Trillion GDP Loss by 2030 due to resistant bacteria8 | Confidential 1. Davey, P. et al. Emerg Infect Dis (2006); 2. Linder, J.et al. JAMA (2001); 3. Cadieux, G et al. CMAJ (2007); 4. Pulc
Slide 29: Conventional tests are important but insufficient
Conventional tests are important but insufficient to effectively aid patient management Prolonged Time Inaccessible Often, Undetected bacterial To Results infection sites no pathogens co-infections are detected | Confidential MeMed, Proprietary and Confidential Information. This document and its con
Slide 30: The vision
The vision A few minutes Small blood volume Decoding fever and more | Confidential MeMed, Proprietary and Confidential Information. This document and its content may not be reproduced, disclosed or passed on to third parties except with the explicit prior consent of MeMed
Slide 31: The paradigm: decoding the body's immune response
The paradigm: decoding the body s immune response | Confidential Bacterial immune response Viral immune response MeMed, Proprietary and Confidential Information. This document and its content may not be reproduced, disclosed or passed on to third parties except with the explicit prior consent of MeM
Slide 32: MeMed BV uses machine learning to integrate three host proteins
MeMed BV® uses machine learning to computationally integrate three host proteins (TRAIL, IP-10, CRP) in minutes Ghrelin G-CSF GM-CSF Machine Learning MeMed BV ® TREM-1 sTNFR1 Gro- / MCP-1 Bacterial TNF TRAIL infection CRP IL-6 Monocytes Leptin IL-10 Neutrophils IFN- IL-8 Endothelium OPN VEGF permeab
Slide 33: BV high performance independently confirmed in blinded validation
BV® high performance independently confirmed in unprecedented blinded validation and real-world evidence of >20,000 patients 100% 90% 80% 70% 60% 50% 98% 93% 90% 92% 91% 94% 40% 30% 20% 10% 0% | Confidential Curiosity Opportunity Pathfinder Rosetta AutoPilot Observer Discovery & 1st External 2nd Ext
Slide 34: Landmark FDA Clearance
Landmark FDA Clearance of 1st Technology to Aid in Distinguishing between Bacterial and Viral Infections Using the Body s Immune Response
Slide 35: Indications
Indications Differential diagnosis Bacterial VS Viral infection Children Suspected acute EDs, Urgent Cares, Can complement direct viral (>3 months) infections and samples detection tests by & adults (LRTI, FWS, URTI, systemic collected at identifying bacterial-viral infections etc.) hospital admissi
Slide 36: MeMed BV is measured on MeMed Key
MeMed BV® is measured on MeMed Key® - enabling central lab precision at the point of need. | Confidential MeMed, Proprietary and Confidential Information. This document and its content may not be reproduced, disclosed or passed on to third parties except with the explicit prior consent of MeMed
Slide 37: Diasorin and MeMed partnership
Diasorin and MeMed partnership - unique complementary capabilities | Confidential MeMed, Proprietary and Confidential Information. This document and its content may not be reproduced, disclosed or passed on to third parties except with the explicit prior consent of MeMed
Slide 38: MeMed BV on Liaison receives CE-Mark
MeMed BV® on Liaison® receives CE-Mark (Nov 2021) | Confidential MeMed, Proprietary and Confidential Information. This document and its content may not be reproduced, disclosed or passed on to third parties except with the explicit prior consent of MeMed
Slide 39: Targeting >$11B market opportunity
Targeting >$11B market opportunity United States EDs and Hospitals: 35M cases USA Global Number of visits $5.3 $11.1 seeking medical Urgent Care: assistance 55M cases Billion Billion 250M Physician office: cases 156M cases Retail Clinics: Potential future upside 5M cases (not included in the estimat
Slide 40: Impacting patient outcome and health economics
Impacting patient outcome and health economics Reducing Improved clinical accuracy uncertainty Informed Affecting Patient Shorter patient Improving Outcomes time to mgmt. Management Course diagnosis decisions Better Saving patient hospital experience costs1 | Confidential 1 Source: Schneider et al.
Slide 41: The Host Response Company
The Host Response Company The immune system is built to communicate what s going on. Our mission is to listen.
Slide 42: DiaSorin and QIAGEN
DiaSorin ossss QIAGEN IMMUNODIAGNosTICS MOLECULAR DIAGNOSTICS LICENSED TECHNOLOGIES
Slide 43: LIAISON QuantiFERON Franchise
LIAISON® QUANTIFERON® FRANCHISE QIAGEN POTENTIAL NEW APPLICATIONS IN THE FUTURE LATENT TUBERCULOSIS patil HES IHOLECULARIDIAGNOSTICS (icenseb TECHNOLOGIES
Slide 44: Latent Tuberculosis Update
LATENT TUBERCULOSIS UPDATE SUCCESS OF THE PROGRAM PROGRAM ALMOST COMPLETED IMMUNODIAGNosTICS > 480 existing customers MOLECULAR DIAGNOSTICS PROGRAM IN PROGRESS ait st > 150 existing customers over an estimated Total Addressable Market of 500+ accounts + Hospitals strategy through LIAISON® XS LICENSE
Slide 45: LIAISON LymeDetect
LIAISON® LYMEDETECT® ale) @) Figs QIAGEN QUANTIFERON TECHNOLOGY AND DIASORIN SEROLOGY TESTING COMBINED TO PROVIDE INCREASED SENSITIVITY IN ACUTE INFECTION DRIVING ANTIBIOTIC THERAPY DECISION Lyme IgG Lyme IgM Lyme QFT IMMUNODIAGNosTICS MOLECULAR DIAGNOSTICS LICENSED TECHNOLOGIES
Slide 46: LIAISON LymeDetect Program Status
LIAISON® LYMEDETECT® PROGRAM STATUS FROM 2024 FULL COMMERCIAL IMPACT PRODUCT DEVELOPMENT REIMBURSEMENT DEMAND GENERATION + Digital patient & GP education program + Healthcare economic model development ONGOING “littl 7 * Clinical studies to support reimbursement 1 . Hi ACTIVITIES ertreteim ' On hold
Slide 47: LIAISON IQ
LIAISON® IQ MOLECULAR DIAGNOSTICS LICENSED TECHNOLOGIES
Slide 48: Pharmacy Markets in USA and Italy
PHARMACY MARKETS IN USA AND ITALY ARE SIGNIFICANTLY DIFFERENT... O third of the total stores!) Regulatory framework is established Regulatory framework in evolution. COVID pandemic accelerated the process + CLIAwaived pharmacies can run IVD (both Molecular and Immuno) : + Capillary blood tests (fing
Slide 49: The Role of Pharmacists in Diagnostics Delivery
..SO IS THE ROLE OF PHARMACISTS IN DIAGNOSTICS DELIVERY MARKET OPPORTUNITY ~20,000 pharmacies Pharmacists can leverage diagnostics to: O 1/3 in rural setting prhenelehenmaciste * Effectively prescribe OTC supplements to support have a key role in the oman P the monitoring of some chronic conditions.
Slide 50: LIAISON XS Program Reloaded
LIAISON® XS PROGRAM RELOADED psf
Slide 51: LIAISON XS Program Reloaded: Hospitals Strategy in the U.S.
LIAISON® XS PROGRAM RELOADED: HOSPITALS STRATEGY IN THE U.S. ~700 EXISTING NEW LUMINEX CUSTOMERS ' cuSTOMERS e Luminex. TOTAL ADDRESSABLE MARKET ~1,200 HOSPITALS POTENTIAL PRODUCTS' PIPELINE *& QrT yk) MeMep BV ye GI PANEL tee GRowTH ke FERTILITY Latent TB, Lyme Total, G & M Calpro, Elastase, H.pylo
Slide 52: LIAISON XXL
LIAISON® XXL a JODIAGNOSTICS MOLECULAR DIAGNOSTICS LICENSED TECHNOLOGIES
Slide 53: Mid-to-Large Volumes
MID-TO-LARGE VOLUMES CUSTOMERS HIGH VOLUME CUSTOMERS / BIG COMMERCIAL LABS LIAISON® CURRENT SITUATION WITH LIAISON® XL ~70% of existing DiaSorin installed base is placed stand-alone (single instrument) LIAISON® XL ~30% of existing DiaSorin installed base is placed with multiple placements XXL POTENT
Slide 54: Approach to Consolidation and Decentralization Trend
APPROACH TO CONSOLIDATION AND DECENTRALIZATION TREND LIAISON’ |Q LIAISON 5< LIAJSON’X< ~—LIAJSON"2¢ LIAJSON"><2< LAS LOW-MEDIUM THROUGHPUT MEDIUM-HIGH THROUGHPUT VERY HIGH THROUGHPUT Expansion in Migration from LIAISON® Strengthening of existing installed Large Labs requiring more efficient Point-Of
Slide 55: Slide 55
Slide 56: Testing Needs Served by Different Molecular Diagnostic Technologies
TESTING NEEDS SERVED BY DIFFERENT MOLECULAR DIAGNOSTIC TECHNOLOGIES Identify pathogen confirming existing clinical suspicion Single target determination through single/low plex technology technology Multiple-target determination through multiplex Identify pathogen in absence of clear clinical suspic
Slide 57: Market Trends
MARKET TRENDS Mature market (low-single digits growth ex-COVID) with a wide spectrum of platforms (from single to high-throughput) Clear distinction between high-throughput application (e.g. HIV, HCV, etc.) and specialty testing Pandemic pushing decentralized testing needs Pandemic increasing adopti
Slide 58: Molecular Diagnostics Offer
MOLECULAR DIAGNOSTICS OFFER LIAISON® MDX we Respiratory Infections : 12 KITS MEDIUM ] Small Panels/Single Analyt Hospryars Vector le Analyte : ~ 400 €/min of 2021 Borne \ (Specific Tests) : “a pro-forma* revenues 1kIT . Real-Time PCR Be : ‘ ’ 7 SINGLE / LOW eal-Time [Ika a PLATFORMS ~ 2,700 forieol
Slide 59: LIAISON MDX Plus
LIAISON® MDX PLUS DiaSorin
Slide 60: Launch of LIAISON MDX Plus
LAUNCH OF LIAISON® MDX PLUS Gg | g Infections Meningo- - Encephalitis MEDIUM \ HOSPITALS Women’s Health ' SINGLE / LOW | PLEX TESTS, } Neonatal SMALL Testing COMMUNITY HOSPITALS LIAISON® MDX Plus Hospital Acquired COMMERCIAL LABS Infections : a “+. Genetics Transplant Vector ne oe Cystic Fibrosis Bo
Slide 61: Slide 61
Slide 62: LIAISON NES
LIAISON® NES DiaSorin
Slide 63: LIAISON NES
LIAISON® NES WIDE MENU AVAILABLE ON A RELIABLE, EASY-TO-USE AND PROFESSIONAL POINT-OF-CARE PLATFORM, FITTING WITH THE DECENTRALIZED SETTING'S NEEDS Main Target Clients/Channel [5 PHYSICIANS 7 | PHARMACY Cloud connection and streamlined data transfer Technology on par with the laboratory offerings HO
Slide 64: Point of Care Benefits
POINT OF CARE BENEFITS | Reduced clinic visits Earlier discharge Less admissions Prompt treatment prescription Reduced staff, equipment Lower out-of-pocket Lower send out Lower Insurance payouts Customer outreach Rural population Mobile testing Disaster sites, emergency calls, military sites, etc.
Slide 65: Slide 65
Slide 66: Molecular Diagnostics Offer
MOLECULAR DIAGNOSTICS OFFER LTIPLEX TECHNOLO ep Medium/Large Panels = = Semi-Automated ———~_— Multiplex PCR (Syndromic) VERIGENE® Infections Bloodstream ~ 100 €/min of 2021 \ pro-forma* revenues PLATFORMS J ~ 1,100 ee installed platforms Multiplex PCR DNA Tags Genetics/cystic . xMAP® Microspheres. F
Slide 67: LIAISON PLEX
LIAISON® PLEX DiaSorin IMMUNODIAGNOSTICS LICENSED TECHNOLOGIES
Slide 68: Launch of LIAISON PLEX
LAUNCH OF LIAISON® PLEX VERIGENE® Respiratory g Infections Bloodstream cNS Infections \ vA (Meningitis) ‘MULTIPLEX| HOSPITAL / REFERENCE PANELS | cape ON CLINICAL LABS . . Genetics/Cystic : . a 100/200 aw mee Fibrosis Gastro-Intestinal .
Slide 69: VERIGENE
VERIGENE NONSHRENEETICS TeETESINOIOSES
Slide 70: Flex the Plex
FLEX THE PLEX Users choose Full Panel or Flex Testing, unmasking additional results with Flex Credits Flex customers view fewer targets at a reduced cost, but can unmask additional results as needed using Flex Credits Customers pay only for tests selected System can scale up for Low, Mid or High-vol
Slide 71: Approach to Consolidation and Decentralization Trend
APPROACH TO CONSOLIDATION AND DECENTRALIZATION TREND LIAISON’ NES LIAJSON’ MDX + LIAJSON’ Plex [ - Menu expansion & Expansion in Point-of-Care instrument enhancement Expansion in Syndromic ° oO, § 50 Oe DECENTRALIZED SETTING LOW-MID VOLUME HIGH VOLUME ofe ryt
Slide 72: Licensed Technologies
q LICENSED TECHNOLOGIES |
Slide 73: Licensed Technologies Overview
LICENSED TECHNOLOGIES OVERVIEW " x¥MAP® Flow Cytometry LICENSED TECHNOLOGIES (LT) ~80% of LT business ~20% of LT business TNUONSHRENETES TEU ENSETES
Slide 74: Licensed Technologies: Deep Dive on xMAP Technology Market
LICENSED TECHNOLOGIES: DEEP DIVE ON xMAP® TECHNOLOGY MARKET 25+ YEARS OF EXPERIENCE IN MULTIPLEXING WITH THE LUMINEX xMAP® VERSATILE MICROSPHERES > FBR 2s +Immunodiagnostic + Transplant Diagnostic Protein > ca) RESEARCH / ACADEMIA + Vaccine Development + Drug Discovery + Cancer Research IMMUNODIAGNO
Slide 75: xMAP Technology: Partnership Opportunities
XMAP® TECHNOLOGY: PARTNERSHIP OPPORTUNITIES . ¢ . , . ) ~ EXISTING LONG-TERM PARTNERSHIPS... ..AND ADDITIONAL OPPORTUNITIES +80+ Partners investing in the technology +Long-term contractual partnerships «New Business Development -Opportunities in large markets XMAP® TECHNOLOGY: INNOVATION AT THE EDGE
Slide 76: Licensed Technologies: The xMAP INTELLIFLEX Platform
LICENSED TECHNOLOGIES: THE xMAP INTELLIFLEX® PLATFORM RELIABLE, SENSITIVE RESULTS CUSTOMIZATION AND FLEXIBILITY MAXIMUM DATA/ANSWERS 500 ANALYTES PER WELL; UP TO 2 PARAMETERS PER ANALYTE NO OTHER MULTIPLEX PLATFORM COMBINES LOW- AND HIGH-PLEX CAPABILITIES, QUICK TIME TO RELIABLE RESULTS, AND THE ABI
Slide 77: Licensed Technologies
TNUONSHRENETES TEU ENSETES
Slide 78: Licensed Technologies: Deep Dive on Flow Cytometry
LICENSED TECHNOLOGIES: DEEP DIVE ON FLOW CYTOMETRY >10,000 INSTRUMENT PLACEMENTS. THOUSANDS OF PUBLICATIONS ON THE TECHNOLOGY ) BROADEST SPECTRUM OF FLOW CYTOMETRY SOLUTIONS ¥ Intuitive ¥ Innovative v Flexible IMAGE-BASED FLOW CYTOMETRY ® KEY NEXT OPPORTUNITIES =e ImageStreamx® Mk I Amnis FlowSight®
Slide 79: Financial Outlook
Slide 80: 2022 Outlook & 2025 Guidance: Total Sales
2022 OUTLOOK & 2025 GUIDANCE @CER*: TOTAL SALES | ~ 1,500 SPECIAL PROGRAMS: ~€/MLN 150 CONTRIBUTION @ 2025 [li susiness ex covin Hi cow’ [— LIAISON® NES |—— LIAISON® LymeDetect '— LIAISON® MeMed BV® Data in €/min 2021 2022 2025 FINANCIAL OUTLOOK moc al Indicative graphic only, not to scale
Slide 81: 2022 Outlook & 2025 Guidance: Sales by Technology
2022 OUTLOOK & 2025 GUIDANCE @CER*: SALES BY TECHNOLOGY | ~-2% | CAGR ~ +7% —- ~ 1,500 EL immunodiagnostics Hh Motecutar Diagnostics EE Licensed technologies IB cov’ Data in €/mIn 2021 2022 2025 FINANCIAL OUTLOOK na 1850 Indicative graphic only, not to scale
Slide 82: 2022 Outlook & 2025 Guidance: Sales by Geography
2022 OUTLOOK & 2025 GUIDANCE @CER*: SALES BY GEOGRAPHY | ~-2% | CAGR ~ +7% —- ~ 1,500 EEE north america Direct HBB europe Direct LBB Rest of the World TB covio' Data in €/min 2021 2022 2025 FINANCIAL OUTLOOK ar 3620 Indicative graphic only, not to scale
Slide 83: Revenues Comparison: 2019 Actual - 2025 Guidance
REVENUES COMPARISON: 2019 ACTUAL - 2025 GUIDANCE @CER* > x= gm - . < @ 44% Europe Direct @ 30% Europe Direct S 2019A { @ 29% North America Direct @ 49% North America Direct 2025¢ ° © 27% ROW @ 18% Row o K @ 3% COVID' ° ‘ > ao > 0 ° , 1 a © 57% Immunodiagnostics s @ 91% Immunodiagnostics @ 23% Molecu
Slide 84: Group Synergies After Luminex Acquisition
GROUP SYNERGIES AFTER LUMINEX ACQUISITION @CER* MAIN DRIVERS OF COST SYNERGIES: Platform Consolidation Geographic Footprint Rationalization Operations and Supply Chain Optimization Organization Integration and Right-Sizing MAIN DRIVERS OF REVENUE SYNERGIES: U.S. Hospital Cross-Selling Leveraging Dia
Slide 85: 2022 Outlook & 2025 Guidance: Adjusted EBITDA Margin
2022 OUTLOOK & 2025 GUIDANCE @CER* ADJUSTED EBITDA** MARGIN + High operating leverage driven + Gross Margin dilution due to product mix + Gross Margin improvement partially by COVID volumes « Reduction of COVID Volumes spp lower offset by royalties on partnership sperating leverage products and prod
Slide 86: Net Debt/Adjusted EBITDA
NET DEBT/ADJUSTED EBITDA* @CER** ~2.1X ~1.9X ~0.5X EB net vebt BB gj. esrroa* : 2021 2022 2023 2024 2025 FINANCIAL OUTLOOK Indicative graphic only, not to scale
Slide 87: 2022 Outlook & 2025 Guidance
2022 OUTLOOK & 2025 GUIDANCE @CER* 2021e 2022e 2025e Notes 22-25 CAGR Revenues ~€ 1,230 min ~€ 1,210 min ~€ 1,500 min ~ +7% with Covid ~ +10% ex Covid Adjusted EBITDA** margin ~43% ~35% ~38% 22:25 Ad. EBITDA™ CAGR Free Cash Flow ~€ 300 min Cumulative 22-25: ~€ 1,100 min Cumulative 22,28 Capex: Net D